IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.22
+3.01%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -72.0%
- EBIT
- -75.8%
- EPS
- -12.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +34.5%
- EPS
- -5.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -37.4%
- EBIT
- -32.1%
- Net income
- -36.2%
- EPS
- -17.1%
- Free cash flow
- -56.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026